Direct interaction between caffeic acid phenethyl ester and human neutrophil elastase inhibits the growth and migration of PANC-1 cells

Duan,Jianhui; Xiaokaiti,Yilixiati; Fan,Shengjun; Pan,Yan; Li,Xin; Li,Xuejun

doi:10.3892/or.2017.5516

Direct interaction between caffeic acid phenethyl ester and human neutrophil elastase inhibits the growth and migration of PANC-1 cells

Authors:
- Jianhui Duan
- Yilixiati Xiaokaiti
- Shengjun Fan
- Yan Pan
- Xin Li
- Xuejun Li
View Affiliations

Affiliations: Department of Pharmacology, School of Basic Medical Sciences, Peking University and State Key Laboratory of Natural and Biomimetic Drugs, Peking University and Beijing Key Laboratory of Tumor Systems Biology, Peking University, Beijing 100191, P.R. China
Published online on: March 21, 2017 https://doi.org/10.3892/or.2017.5516
Pages: 3019-3025

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignant tumors of the digestive system, but the mechanisms of its development and progression are unclear. Inflammation is thought to be fundamental to pancreatic cancer development and caffeic acid phenethyl ester (CAPE) is an active component of honey bee resin or propolis with anti-inflammatory and anticancer activities. We investigated the inhibitory effects of CAPE on cell growth and migration induced by human neutrophil elastase (HNE) and report that HNE induced cancer cell migration at low doses and growth at higher doses. In contrast, lower CAPE doses inhibited migration and higher doses of CAPE inhibited the growth induced by HNE. HNE activity was significantly inhibited by CAPE (7.5-120 µM). Using quantitative real-time PCR and western blotting, we observed that CAPE (18-60 µM) did not affect transcription and translation of α1-antitrypsin (α1-AT), an endogenous HNE inhibitor. However, in an in silico drug target docking model, we found that CAPE directly bound to the binding pocket of HNE (25.66 kcal/mol) according to CDOCKER, and the residue of the catalytic site stabilized the interaction between CAPE and HNE as evidenced by molecular dynamic simulation. Response unit (RU) values of surface plasmon resonance (SPR) significantly increased with incremental CAPE doses (7.5-120 µM), indicating that CAPE could directly bind to HNE in a concentration-dependent manner. Thus, CAPE is an effective inhibitor of HNE via direct interaction whereby it inhibits the migration and growth of PANC-1 cells in a dose-dependent manner.

View Figures

View References

1	Paulson AS, Cao Tran HS, Tempero MA and Lowy AM: Therapeutic advances in pancreatic cancer. Gastroenterology. 144:1316–1326. 2013. View Article : Google Scholar : PubMed/NCBI
2	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
3	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
4	Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM and Matrisian LM: Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 74:2913–2921. 2014. View Article : Google Scholar : PubMed/NCBI
5	Reid MD, Basturk O, Thirabanjasak D, Hruban RH, Klimstra DS, Bagci P, Altinel D and Adsay V: Tumor-infiltrating neutrophils in pancreatic neoplasia. Mod Pathol. 24:1612–1619. 2011. View Article : Google Scholar : PubMed/NCBI
6	Gaida MM, Steffen TG, Günther F, Tschaharganeh DF, Felix K, Bergmann F, Schirmacher P and Hänsch GM: Polymorphonuclear neutrophils promote dyshesion of tumor cells and elastase-mediated degradation of E-cadherin in pancreatic tumors. Eur J Immunol. 42:3369–3380. 2012. View Article : Google Scholar : PubMed/NCBI
7	Sköld CM, Liu X, Umino T, Zhu Y, Ohkuni Y, Romberger DJ, Spurzem JR, Heires AJ and Rennard SI: Human neutrophil elastase augments fibroblast-mediated contraction of released collagen gels. Am J Respir Crit Care Med. 159:1138–1146. 1999. View Article : Google Scholar : PubMed/NCBI
8	Kouakou-Siransy G, Sahpaz S, Nguessan GI, Datté JY, Brou JK, Gressier B and Bailleul F: Effects of Alchornea cordifolia on elastase and superoxide anion produced by human neutrophils. Pharm Biol. 48:128–133. 2010. View Article : Google Scholar : PubMed/NCBI
9	Sato T, Takahashi S, Mizumoto T, Harao M, Akizuki M, Takasugi M, Fukutomi T and Yamashita J: Neutrophil elastase and cancer. Surg Oncol. 15:217–222. 2006. View Article : Google Scholar : PubMed/NCBI
10	Lucas SD, Costa E, Guedes RC and Moreira R: Targeting COPD: Advances on low-molecular-weight inhibitors of human neutrophil elastase. Med Res Rev. 33:(Suppl 1). E73–E101. 2013. View Article : Google Scholar : PubMed/NCBI
11	Siedle B, Hrenn A and Merfort I: Natural compounds as inhibitors of human neutrophil elastase. Planta Med. 73:401–420. 2007. View Article : Google Scholar : PubMed/NCBI
12	McKay CJ, Glen P and McMillan DC: Chronic inflammation and pancreatic cancer. Best Pract Res Clin Gastroenterol. 22:65–73. 2008. View Article : Google Scholar : PubMed/NCBI
13	Greer JB and Whitcomb DC: Inflammation and pancreatic cancer: An evidence-based review. Curr Opin Pharmacol. 9:411–418. 2009. View Article : Google Scholar : PubMed/NCBI
14	Sun Z and Yang P: Role of imbalance between neutrophil elastase and alpha 1-antitrypsin in cancer development and progression. Lancet Oncol. 5:182–190. 2004. View Article : Google Scholar : PubMed/NCBI
15	Kamohara H, Sakamoto K, Mita S, An XY and Ogawa M: Neutrophil elastase inhibitor (ONO-5046.Na) suppresses the proliferation, motility and chemotaxis of a pancreatic carcinoma cell line, Capan-1. Res Commun Mol Pathol Pharmacol. 98:103–108. 1997.PubMed/NCBI
16	Tolba MF, Azab SS, Khalifa AE, Abdel-Rahman SZ and Abdel-Naim AB: Caffeic acid phenethyl ester, a promising component of propolis with a plethora of biological activities: A review on its anti-inflammatory, neuroprotective, hepatoprotective, and cardioprotective effects. IUBMB Life. 65:699–709. 2013. View Article : Google Scholar : PubMed/NCBI
17	Chan GC, Cheung KW and Sze DMP: The immunomodulatory and anticancer properties of propolis. Clin Rev Allergy Immunol. 44:262–273. 2013. View Article : Google Scholar : PubMed/NCBI
18	Akyol S, Ozturk G, Ginis Z, Armutcu F, Yigitoglu MR and Akyol O: In vivo and in vitro antineoplastic actions of caffeic acid phenethyl ester (CAPE): Therapeutic perspectives. Nutr Cancer. 65:515–526. 2013. View Article : Google Scholar : PubMed/NCBI
19	Watanabe MA, Amarante MK, Conti BJ and Sforcin JM: Cytotoxic constituents of propolis inducing anticancer effects: A review. J Pharm Pharmacol. 63:1378–1386. 2011. View Article : Google Scholar : PubMed/NCBI
20	Melzig MF, Pertz HH and Krenn L: Anti-inflammatory and spasmolytic activity of extracts from Droserae herba. Phytomedicine. 8:225–229. 2001. View Article : Google Scholar : PubMed/NCBI
21	Fan S, Xu Y and Li X, Tie L, Pan Y and Li X: Opposite angiogenic outcome of curcumin against ischemia and Lewis lung cancer models: In silico, in vitro and in vivo studies. Biochim Biophys Acta. 1842:1742–1754. 2014. View Article : Google Scholar : PubMed/NCBI
22	Xu Y, Zhang J, Han J, Pan X, Cao Y, Guo H, Pan Y, An Y and Li X: Curcumin inhibits tumor proliferation induced by neutrophil elastase through the upregulation of α1-antitrypsin in lung cancer. Mol Oncol. 6:405–417. 2012. View Article : Google Scholar : PubMed/NCBI
23	Chen MJ, Shih SC, Wang HY, Lin CC, Liu CY, Wang TE, Chu CH and Chen YJ: Caffeic Acid phenethyl ester inhibits epithelial-mesenchymal transition of human pancreatic cancer cells. Evid Based Complement Alternat Med. 2013:2709062013.PubMed/NCBI
24	Chen MJ, Chang WH, Lin CC, Liu CY, Wang TE, Chu CH, Shih SC and Chen YJ: Caffeic acid phenethyl ester induces apoptosis of human pancreatic cancer cells involving caspase and mitochondrial dysfunction. Pancreatology. 8:566–576. 2008. View Article : Google Scholar : PubMed/NCBI
25	Hausmann S, Kong B, Michalski C, Erkan M and Friess H: The role of inflammation in pancreatic cancer. Adv Exp Med Biol. 816:129–151. 2014. View Article : Google Scholar : PubMed/NCBI
26	Momi N, Kaur S, Krishn SR and Batra SK: Discovering the route from inflammation to pancreatic cancer. Minerva Gastroenterol Dietol. 58:283–297. 2012.PubMed/NCBI
27	Kolodecik T, Shugrue C, Ashat M and Thrower EC: Risk factors for pancreatic cancer: Underlying mechanisms and potential targets. Front Physiol. 4:4152014. View Article : Google Scholar : PubMed/NCBI
28	Aikawa N and Kawasaki Y: Clinical utility of the neutrophil elastase inhibitor sivelestat for the treatment of acute respiratory distress syndrome. Ther Clin Risk Manag. 10:621–629. 2014.PubMed/NCBI
29	Novovic S, Andersen AM, Nord M, Astrand M, Ottosson T, Jørgensen LN and Hansen MB: Activity of neutrophil elastase reflects the progression of acute pancreatitis. Scand J Clin Lab Invest. 73:485–493. 2013. View Article : Google Scholar : PubMed/NCBI
30	Nawa M, Osada S, Morimitsu K, Nonaka K, Futamura M, Kawaguchi Y and Yoshida K: Growth effect of neutrophil elastase on breast cancer: Favorable action of sivelestat and application to anti-HER2 therapy. Anticancer Res. 32:13–19. 2012.PubMed/NCBI
31	Nishiyama J, Matsuda M, Ando S, Hirasawa M, Suzuki T and Makuuchi H: The effects of the early administration of sivelestat sodium, a selective neutrophil elastase inhibitor, on the postoperative course after radical surgery for esophageal cancer. Surg Today. 42:659–665. 2012. View Article : Google Scholar : PubMed/NCBI
32	Hanada N, Kusano S, Hori K and Momi H: Good response in ARDS treated with sivelestat sodium hydrate during chemotherapy for cholangiocarcinoma. Gan To Kagaku Ryoho. 34:1303–1306. 2007.(In Japanese). PubMed/NCBI
33	Wada Y, Yoshida K, Hihara J, Konishi K, Tanabe K, Ukon K, Taomoto J, Suzuki T and Mizuiri H: Sivelestat, a specific neutrophil elastase inhibitor, suppresses the growth of gastric carcinoma cells by preventing the release of transforming growth factor-alpha. Cancer Sci. 97:1037–1043. 2006. View Article : Google Scholar : PubMed/NCBI
34	Aparoy P, Reddy KK and Reddanna P: Structure and ligand based drug design strategies in the development of novel 5-LOX inhibitors. Curr Med Chem. 19:3763–3778. 2012. View Article : Google Scholar : PubMed/NCBI
35	Crauste C, Willand N, Villemagne B, Flipo M, Willery E, Carette X, Dimala MM, Drucbert AS, Danze PM, Deprez B, et al: Unconventional surface plasmon resonance signals reveal quantitative inhibition of transcriptional repressor EthR by synthetic ligands. Anal Biochem. 452:54–66. 2014. View Article : Google Scholar : PubMed/NCBI